Crosspoint Capital Strategies’s Bristol-Myers Squibb BMY Stock Holding History

Crosspoint Capital Strategies’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-3,038	Closed	-$189K	–	194
2015 Q4	$189K	Buy	3,038 +1,160	+62%	+$76.7K	0.05%	241
2015 Q3	$111K	Buy	1,878 +1,178	+168%	+$74.7K	0.13%	156
2015 Q2	$47K	Buy	+700	New	+$46.1K	0.01%	352
2015 Q1	–	Sell	-31,630	Closed	-$1.87M	–	533
2014 Q4	$1.87M	Sell	31,630 -227	-0.7%	-$12.8K	0.65%	44
2014 Q3	$1.63M	Buy	31,857 +1,219	+4%	+$60.9K	1.21%	19
2014 Q2	$1.53M	Buy	30,638 +4,007	+15%	+$197K	0.58%	48
2014 Q1	$1.38M	Buy	26,631 +258	+1%	+$13.7K	0.56%	43
2013 Q4	$1.49M	Buy	+26,373	New	+$1.34M	0.5%	48

Other funds holding BMY

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Crosspoint Capital Strategies's BMY Position: Q1 2016 in Review

Crosspoint Capital Strategies sold out of Bristol-Myers Squibb (BMY) in Q1 2016, closing a stake of 3,038 shares — an estimated $189K sold.

Crosspoint Capital Strategies first reported a position in BMY in Q4 2013 and held it in 8 quarters. The position peaked at $1.87M in Q4 2014. 1,523 funds tracked by Wall St. Rank hold BMY as of Q1 2016.

Crosspoint Capital Strategies reported no remaining Bristol-Myers Squibb position as of Q1 2016 after selling out during the quarter.
Crosspoint Capital Strategies sold 3,038 Bristol-Myers Squibb shares in Q1 2016, an estimated $189K.
Crosspoint Capital Strategies first reported a position in Bristol-Myers Squibb in Q4 2013 and held it in 8 quarters.
Crosspoint Capital Strategies's Bristol-Myers Squibb position peaked at $1.87M in Q4 2014.
1,523 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2016.

Based on Crosspoint Capital Strategies's 13F filing for Q1 2016, filed 16 May 2016.